Oorsprong van het eerstegraads netwerk van Mark G. Egan
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Mark G. Egan via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
PEPSICO, INC. | Food: Specialty/Candy | Director/Board Member | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer | |
MOLMED S.P.A. | Pharmaceuticals: Major | Chairman | |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Investment Officer | |
University of Oxford | College/University | Undergraduate Degree | |
Novartis Pharmaceuticals UK Ltd.
Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
University of Cambridge | College/University | Masters Business Admin | |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
University College London | College/University | Doctorate Degree | |
University of Zurich | College/University | Undergraduate Degree Doctorate Degree | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Private Equity Investor | |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
American Academy of Arts & Sciences
American Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services The American Academy of Arts & Sciences is an organization that honors excellence and brings together leaders. The non-profit company is based in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Apposite Capital LLP
Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal | |
EryDel SpA
EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Medical Specialties | Chairman | |
The European Association for Bioindustries | Chairman | ||
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Director of Investments | |
Università degli Studi di Modena e Reggio Emilia | College/University | Doctorate Degree | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member | |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Epsilon-3 Bio Ltd
Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member | |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
OBSEVA SA | Pharmaceuticals: Major | Director/Board Member | |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
Glionova AB
Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member | |
mPharma Health Nigeria Ltd.
mPharma Health Nigeria Ltd. Packaged SoftwareTechnology Services mPharma Health Nigeria Ltd. engages in the development of a pharmaceutical data management platform. The company was founded by Gregory Rockson, Dan Shoukimas and James Finucane in 2013 and is headquartered in Accra, Ghana. | Packaged Software | Director/Board Member | |
mPharma Data, Inc.
mPharma Data, Inc. Packaged SoftwareTechnology Services mPharma Data, Inc. engages in the development of an application that enables physicians to prescribe and locate medicines for patients. The company is headquartered in Lexington, MA. | Packaged Software | Director/Board Member | |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member | |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member | |
INVENTIVA | Biotechnology | Director/Board Member | |
ImClone Systems LLC
ImClone Systems LLC BiotechnologyHealth Technology Part of Eli Lilly & Co., ImClone Systems LLC is a company that develops and manufactures biologics for the treatment of cancer. The company is based in Bridgewater, NJ. | Biotechnology | Corporate Officer/Principal | |
International Rare Diseases Research Consortium | Corporate Officer/Principal | ||
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Miscellaneous Commercial Services | Director/Board Member | |
LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member | |
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member | |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chairman | |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Gotham Therapeutics Corp.
Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chairman | |
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED | Pharmaceuticals: Major | Director/Board Member | |
DYNE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chairman | |
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
Denemarken | 11 |
Verenigd Koninkrijk | 11 |
Verenigde Staten | 10 |
Zwitserland | 7 |
Italië | 4 |
Sectoraal
Health Technology | 31 |
Finance | 6 |
Consumer Services | 6 |
Commercial Services | 6 |
Technology Services | 3 |
Operationeel
Director/Board Member | 47 |
Corporate Officer/Principal | 18 |
Chairman | 13 |
Chief Tech/Sci/R&D Officer | 9 |
Independent Dir/Board Member | 8 |
Sterkste connecties
Insiders | |
---|---|
Nanna Liebach Lüneborg | 29 |
Daniel Vasella | 25 |
Carlo Incerti | 14 |
Zhen Ping Zhu | 12 |
Peter Lichtlen | 10 |
David Urech | 4 |
Oliver Middendorp | 1 |
Ignacio Melero | 1 |
- Beurs
- Insiders
- Mark G. Egan
- Bedrijfsconnecties